Deferiprone: Clinical Trials

24 trials of Deferiprone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 5 unknown, 3 recruiting, 1 active not recruiting. 24 Phase 2, 6 Phase 3, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 224Completed 14, Unknown 5, Recruiting 3, Active not recruiting 1, Terminated 1
Phase 36Unknown 4, Completed 2
Phase 13Completed 2, Active not recruiting 1

Follow Deferiprone: new trials by email Literature Review of Deferiprone trials Research Report on Deferiprone

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
Deferiprone (DFP), N-Acetyl Cysteine (NAC) - Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder
Phase 2RecruitingAmit Lotan802026-08-122026-09-29
Early Screening and Treatment of Heart Complication in Sickle Cell Disease
Deferoxamine, Deferasirox, Deferiprone - Sickle Cell Disease
Phase 2RecruitingInova Health Care Services1002025-10-072026-09-09
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Deferiprone Tablets, Placebo - Acute Myocardial Infarction Type 1
Phase 2RecruitingRohan Dharmakumar892022-11-082026-09-29
Ferritin and Iron Burden in SAH sIRB
Deferiprone pill, placebo, Montreal Cognitive Assessment - SAH, Dementia
Phase 1 / Phase 2Active not recruitingDuke University662020-10-012026-07-20
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage) - Iron Overload Due to Repeated Red Blood Cell Transfusions
Phase 2CompletedApoPharma302019-03-062021-07-16
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis
Deferiprone, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3CompletedUniversity Hospital, Lille3722019-01-302025-12-05
Deferiprone to Delay Dementia (The 3D Study)
Deferiprone 600mg delayed release tablets, Placebo Oral Tablet - Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Phase 2CompletedNeuroscience Trials Australia812018-01-192024-07-03
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
Deferiprone, Acetylcysteine, Sitagliptin and Metformin - Diabetes Mellitus, Iron Metabolism Disorders
Phase 2 / Phase 3UnknownHadassah Medical Organization202016-12-012016-08-29
Study of Parkinson's Early Stage With Deferiprone
Deferiprone, Placebo - Parkinson's Disease
Phase 2CompletedApoPharma1402016-10-122024-04-10
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease
Deferiprone, Placebo - Parkinson Disease
Phase 2CompletedUniversity Hospital, Lille3722016-02-092026-02-05
Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients
Deferiprone - Myelodysplastic Syndrome With Low-grade Lesions, Iron Overload Due to Repeated Red Blood Cell Transfusions
Phase 2CompletedSheba Medical Center192016-02-012018-11-01
An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
Deferiprone - Beta Thalassemia Major
Phase 2 / Phase 3UnknownAin Shams University642014-07-012015-01-14
Role of Vitamin C to Augment Iron Chelation With DFP or DFX
Vitamin C, Defriprone, deferisarox, deferiprone , deferesarox - Vitamin c, Thalassemia Major
Phase 2 / Phase 3UnknownAin Shams University502014-04-012014-03-11
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
Deferiprone - ALS (Amyotrophic Lateral Sclerosis), Iron Overload
Phase 2CompletedUniversity Hospital, Lille232013-09-012026-02-20
Pharmacokinetic Study of Deferiprone in Paediatric Patients
Deferiprone, dose level 1, Deferiprone, dose level 2, Deferiprone, dose level 3 - Chronic Iron Overload
Phase 2CompletedConsorzio per Valutazioni Biologiche e Farmacologiche232012-12-012017-01-11
Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
Deferasirox and deferiprone - Thalassemia Major With Severe Transfusional Iron Overload
Phase 1 / Phase 2CompletedChildren's Hospital of Philadelphia92012-09-012019-03-06
Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO - Beta-thalassemia Major, Sickle Cell Disease
Phase 2 / Phase 3UnknownAin Shams University602012-02-012012-02-06
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
Deferiprone 20mg, Placebo, Deferiprone 30mg - Parkinson's Disease
Phase 2CompletedImperial College London222012-02-012020-06-16
Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease
deferiprone, placebo - Parkinson's Disease
Phase 2 / Phase 3CompletedUniversity Hospital, Lille402009-10-012026-05-14
A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia
Deferiprone oral solution 100mg/mL, Deferiprone oral solution 100 mg/mL - Friedreich's Ataxia
Phase 2CompletedApoPharma362009-06-012011-06-27

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Iron Overload (5)  ·  beta-Thalassemia (5)  ·  Parkinson Disease (4)  ·  Amyotrophic Lateral Sclerosis (2)  ·  Anemia, Sickle Cell (2)  ·  Dementia (2)  ·  Friedreich Ataxia (2)  ·  Thalassemia (2)  ·  Alzheimer Disease (1)  ·  Arrhythmias, Cardiac (1)  ·  Cardiomyopathies (1)  ·  Cardiovascular Diseases (1)  ·  Cognitive Dysfunction (1)  ·  Diabetes Mellitus (1)  ·  Hearing Loss, Sensorineural (1)

Sponsors

ApoPharma (4)  ·  University Hospital, Lille (4)  ·  Ain Shams University (3)  ·  Amit Lotan (1)  ·  Carelon Research (1)  ·  Children's Hospital of Philadelphia (1)  ·  Consorzio per Valutazioni Biologiche e Farmacologiche (1)  ·  Duke University (1)  ·  Ente Ospedaliero Ospedali Galliera (1)  ·  Hadassah Medical Organization (1)  ·  Imperial College London (1)  ·  Inova Health Care Services (1)  ·  Lipomed (1)  ·  Neuroscience Trials Australia (1)  ·  Rohan Dharmakumar (1)

Countries

France (7)  ·  United States (6)  ·  Italy (5)  ·  Egypt (4)  ·  Canada (3)  ·  Israel (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Belgium (2)  ·  Germany (2)  ·  Austria (1)  ·  Cyprus (1)  ·  Czechia (1)  ·  Greece (1)

Top investigators

Arnold Munnich, M.D. (2)  ·  David Devos, MD, PhD (2)  ·  Massimo Pandolfo, M.D. (2)  ·  Ashley I. Bush (1)  ·  Caroline Moreau, MD (1)  ·  David Devos, MD (1)  ·  David Devos, MD,PhD (1)  ·  David Hasan, MD (1)  ·  David T Dexter, PhD (1)  ·  David Zangen, Professor (1)  ·  Drorit Merkel, MD (1)  ·  Elliott P, Vichinsky, MD (1)  ·  Ellis J. Neufeld, MD (1)  ·  Franco Taroni (1)  ·  Franco Taroni, M.D. (1)

Results publications

PMID 37975597, PMID 11054091, PMID 16540422, PMID 17976187, PMID 18704280, PMID 20938663, PMID 21599434, PMID 21791473, PMID 2265118, PMID 23937987, PMID 24251381, PMID 25600572, PMID 25943368, PMID 28469157, PMID 29119631, PMID 29287521, PMID 29380903, PMID 32726602, PMID 33236783, PMID 36449420, PMID 37975798, PMID 39495531, PMID 39952690, PMID 39973479, PMID 8047081, PMID 8619408, PMID 8959943, PMID 9633879

NIH funding

2008 (1), 2015 (1), 2017 (1), R01HL133407 (1), U01HL065232 (1), U01HL065238 (1), U01HL065239 (1), U01HL065244 (1), U01HL065260 (1)